Lenalidomide maintenance treatment demonstrates significant overall survival benefit following HDT-ASCT

Meta-analysis of results from three randomised control trials has demonstrated that maintenance treatment with lenalidomide (Revlimid®) following high-dose therapy and autologous stem cell transplantation (HDT-ASCT) in newly diagnosed myeloma patients has a significant overall survival (OS) benefit. Published in the Journal of Clinical Oncology, the results of this meta-analysis, which used data pooled from the…

News

IMWG Consensus statement on the role of 18F-FDG PET/CT in the diagnosis and management of myeloma and related diseases

This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of  18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.

Read article

Clinical guidelines & position statements, Imaging & Analysis, IMWG, Library

Guidelines for screening and management of late and long-term consequences of myeloma and its treatment

These guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.

Snowden et al. (2017) British Journal of Haematology

BCSH/UKMF, Clinical guidelines & position statements, Library, Management & Treatment